| Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease |
23 |
| Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event |
22 |
| Progressive multifocal leukoencephalopathy treated with nivolumab |
15 |
| White matter damage, neuroinflammation, and neuronal integrity in HAND |
12 |
| Changing clinical phenotypes of HIV-associated neurocognitive disorders |
10 |
| Interferon-free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health |
10 |
| Progressive brain atrophy in chronically infected and treated HIV plus individuals |
8 |
| Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm |
8 |
| Microglial cell depletion is fatal with low levelpicornavirus infection of the central nervous system |
8 |
| Pathogenesis of age-related HIV neurodegeneration |
7 |
| Astrocytes as an HIV CNS reservoir: highlights and reflections of an NIMH-sponsored symposium |
7 |
| Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy |
7 |
| Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV/neuroAIDS model |
7 |
| Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research |
6 |
| Evolution of the HIV-1 transgenic rat: utility in assessing the progression of HIV-1-associated neurocognitive disorders |
6 |
| Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia |
6 |
| JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy |
6 |
| Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study |
5 |
| Plasma (1 -> 3)-beta-d-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis |
5 |
| Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes |
5 |
| A composite of multisystem injury and neurocognitive impairment in HIV infection: association with everyday functioning |
5 |
| Aging and Apolipoprotein E in HIV Infection |
5 |
| Altered cerebro-cerebellum resting-state functional connectivity in HIV-infected male patients |
5 |
| Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer's disease? |
5 |
| Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders |
5 |
| Neural response to working memory demand predicts neurocognitive deficits in HIV |
5 |
| HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity |
5 |
| HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency |
5 |
| Incidence of symptomatic CSF viral escape in HIV infected patients receiving atazanavir/ritonavir (ATV/r)-containing ART: a tertiary care cohort in western India |
4 |
| An SIV/macaque model targeted to study HIV-associated neurocognitive disorders |
4 |
| Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable |
4 |
| Cigarette smoke and nicotine effects on brain proinflammatory responses and behavioral and motor function in HIV-1 transgenic rats |
4 |
| Empiric neurocognitive performance profile discovery and interpretation in HIV infection |
4 |
| Insular cortex lesion and autonomic instability in a herpes simplex virus encephalitis patient |
4 |
| HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate |
4 |
| Zika virus outbreak: a review of neurological complications, diagnosis, and treatment options |
4 |
| Zika virus-induced acute myelitis and motor deficits in adult interferon alpha beta/gamma receptor knockout mice |
4 |
| Astrocyte activation and altered metabolism in normal aging, age-related CNS diseases, and HAND |
4 |
| Zika virus outbreak in New Caledonia and Guillain-Barre syndrome: a case-control study |
4 |
| Basal ganglia shrinkage without remarkable hippocampal atrophy in chronic aviremic HIV-positive patients |
4 |
| Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial |
4 |
| Neurocognitive impairment is worse in HIV/HCV-coinfected individuals with liver dysfunction |
4 |
| Polymorphisms in CAMKK2 associate with susceptibility to sensory neuropathy in HIV patients treated without stavudine |
4 |
| Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals |
4 |
| Inflammation-related genes are associated with epigenetic aging in HIV |
4 |
| Zika virus induces astrocyte differentiation in neural stem cells |
3 |
| Disturbances of mitochondrial dynamics in cultured neurons infected with human herpesvirus type 1 and type 2 |
3 |
| Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C |
3 |
| Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda |
3 |
| Extrapyramidal motor signs in older adults with HIV disease: frequency, 1-year course, and associations with activities of daily living and quality of life |
3 |
